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Abstract
Introduction: Post-operative outcomes may be improved by the use of flow related end-points for intra-venous
fluid and/or low dose inotropic therapy. The mechanisms underlying this benefit remain uncertain. The objective of
this study was to assess the effects of stroke volume guided intra-venous fluid and low dose dopexamine on tissue
microvascular flow and oxygenation and inflammatory markers in patients undergoing major gastrointestinal
surgery.
Methods: Randomised, controlled, single blind study of patients admitted to a university hospital critical care unit
following major gastrointestinal surgery. For eight hours after surgery, intra-venous fluid therapy was guided by
measurements of central venous pressure (CVP group), or stroke volume (SV group). In a third group stroke volume
guided fluid therapy was combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group).
Results: 135 patients were recruited (n = 45 per group). In the SV & DPX group, increased global oxygen delivery
was associated with improved sublingual (P < 0.05) and cutaneous microvascular flow (P < 0.005) (sublingual
microscopy and laser Doppler flowmetry). Microvascular flow remained constant in the SV group but deteriorated
in the CVP group (P < 0.05). Cutaneous tissue oxygen partial pressure (PtO2) (Clark electrode) improved only in the
SV & DPX group (P < 0.001). There were no differences in serum inflammatory markers. There were no differences
in overall complication rates between the groups although acute kidney injury was more frequent in the CVP
group (CVP group ten patients (22%); pooled SV and SV & DPX groups seven patients (8%); P = 0.03) (post hoc
analysis).
Conclusions: Stroke volume guided fluid and low dose inotropic therapy was associated with improved global
oxygen delivery, microvascular flow and tissue oxygenation but no differences in the inflammatory response to
surgery. These observations may explain improved clinical outcomes associated with this treatment in previous
trials.
Trial registration number: ISRCTN 94850719
Introduction
Complications are common following major non-cardiac
surgery and represent an important cause of avoidable
morbidity and mortality [1-3]. Estimates suggest that as
many as 234 million major surgical procedures are per-
formed worldwide each year, around 15% of which fall
into a high-risk sub-group [2-4]. With mortality rates of
up to 12%, this high-risk surgical population accounts for
over 80% of early post-operative deaths [2,3]. Long-term
survival is also significantly reduced following surgery, in
particular for those patients who develop complications
[5-7]. Importantly, survival among patients who develop
post-operative complications varies widely between hos-
pitals, confirming both the potential and the need to
improve clinical outcomes in this population [8].
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quate global oxygen delivery (DO2), reduced venous
oxygen saturation (mixed venous haemoglobin satura-
tion with oxygen (SvO2) central venous haemoglobin
saturation with oxygen (ScvO2)) and poor outcomes fol-
lowing major surgery is well recognised [9-11]. In sev-
eral relatively small studies, the use of these variables as
treatment end-points for intravenous fluid and inotropic
therapy has been associated with improved clinical out-
comes [12-18]. It has long been suggested that these
beneficial effects relate to improved tissue perfusion and
oxygenation. This may prevent the evolution of a tissue
‘oxygen debt’ and hence reduce the incidence of compli-
cations and organ dysfunction [19]. This theory is con-
sistent with the findings of a number of studies
demonstrating that impaired tissue microvascular flow
and oxygenation are associated with subsequent post-
operative complications [20-24]. In patients with severe
sepsis, there is some evidence to suggest that abnormal-
ities of microvascular flow may cause tissue hypoxia
[25,26], while the use of vasoactive drug therapy has
been shown to improve both tissue microvascular flow
and oxygenation in this group [27-29]. Importantly,
dopexamine, the agent most often used in trials of peri-
operative cardiac output-guided therapies, has a combi-
nation of vasodilator and mild inotropic actions, which
may enhance microvascular flow and improve outcomes
[12]. The findings of recent systematic reviews suggest
that cardiac output guided haemodynamic therapy may
have particular beneficial effects on splanchnic perfusion
and renal function [30,31]. It is also possible that perio-
perative haemodynamic optimisation could favourably
influence the systemic inflammatory response to tissue
injury associated with surgery, thereby reducing the inci-
dence and severity of complications and organ
dysfunction.
Clearly, the hypothesis that perioperative cardiac out-
put-guided haemodynamic therapies result in improved
tissue microvascular flow and oxygenation is plausible
but, after many years, still remains untested. It is also
uncertain whether low-dose inotropic therapy offers
incremental benefit over the use of fluid alone to
achieve cardiac output-related end-points. A detailed
understanding of the physiological effects of haemody-
namic therapies is therefore necessary to provide a
rational basis from which to adapt and refine their use
in clinical practice. The aim of this investigation was to
evaluate the effects of stroke volume-guided intravenous
fluid therapy with and without low-dose dopexamine on
tissue microvascular flow and oxygenation and systemic
markers of inflammation in patients admitted to critical
care following major gastrointestinal surgery.
Materials and methods
Patients scheduled for admission to critical care follow-
ing major elective gastrointestinal surgery were eligible
for recruitment. Exclusion criteria were refusal of con-
sent, pregnancy, patients receiving palliative treatment
only and acute arrhythmias or myocardial ischaemia
prior to enrolment. In addition, patients receiving
lithium therapy or those with a body mass less than
40 kg were excluded because lithium indicator dilution
measurement of cardiac output is not licensed in such
patients. The study was approved by the Research Ethics
Committee and Medical and Healthcare products Regu-
latory Agency (UK). Written informed consent was
obtained from all patients prior to surgery. Participants
were randomly allocated to one of three treatment
groups by computer-generated random sequence in
blocks of nine. Groups were stratified according to sur-
gical procedure (upper gastrointestinal surgery, lower
gastrointestinal surgery and pancreatic surgery involving
the gut). Study group allocations were placed in serially
numbered opaque envelopes.
Clinical management
General anaesthesia was standardised and included
intravenous fentanyl, propofol and atracurium for induc-
tion of anaesthesia and maintenance with inhaled iso-
flurane in oxygen-enriched air and epidural analgesia.
Clinical staff administered intravenous fluids, blood pro-
ducts and, if required, vasoactive drugs in order to
maintain routine physiological, haematological and bio-
chemical parameters within normal ranges as follows:
pulse rate (60 to 100 bpm), mean arterial pressure (60
to 100 mmHg), central venous pressure (CVP) (6 to 12
mmHg), urine output (> 25 ml/hr), haemoglobin (> 8 g/
dl), SpO2 (> 94%), temperature (36 to 37°C), serum base
excess (-2 to +2 mmol/l) and partial pressure of arterial
carbon dioxide (PaCO2; 35 to 45 mmHg). Cardiac out-
put monitoring was not used during surgery. Following
surgery, all patients were admitted to critical care. For
the eight-hour intervention period, either a doctor (SJ)
or nurse (AVS, SLA) administered one of three allocated
haemodynamic protocols as described below. These pro-
tocols are similar to those used in a previous trial [16].
CVP group
Intravenous lactated Ringer’s solution was administered
at 1 ml/kg/hr for maintenance requirements. Patients
received additional 250 ml fluid challenges with intrave-
nous colloid solution (Gelofusine, BBraun, Melsungen,
Germany) to achieve an optimal value of CVP. Colloid
solution was administered in one or more rapid boluses
to achieve a sustained rise in CVP of at least 2 mmHg
for 20 minutes or more. If CVP decreased, fluid
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patient was fluid responsive.
SV group
Intravenous lactated Ringer’s solution was administered
at 1 ml/kg/hr. Patients received additional 250 ml fluid
challenges with intravenous colloid solution to achieve
an optimal value of stroke volume. Colloid solution was
administered in one or more rapid boluses to identify
whether the patient was fluid responsive. A stroke
volume response to fluid was defined as a sustained rise
in stroke volume of at least 10% for 20 minutes or
more. When a patient was identified as stroke volume
responsive to fluid, further 250 ml boluses of fluid were
administered until a plateau value was achieved. If
stroke volume decreased, fluid challenges were repeated
to establish whether the patient was fluid responsive.
SV & DPX group
Intravenous lactated Ringer’s solution was administered
at 1 ml/kg/hr. Patients received additional fluid chal-
lenges with colloid solution to achieve an optimal value
of stroke volume in an identical fashion to patients in
the SV group. In addition, a continuous intravenous
infusion of dopexamine was administered at 0.5 μg/kg/
min (Cephalon, Welwyn Garden City, UK). This infu-
sion rate was not adjusted to achieve a specific value for
cardiac output or DO2 index (DO2I) but was decreased
or discontinued in patients with evidence of myocardial
ischaemia or tachycardia (> 100 bpm or increase > 20%
from baseline value, whichever was greater).
Only the member of the research team who delivered
t h ei n t e r v e n t i o nw a sa w a r eo ft h es t u d yg r o u pa l l o c a -
tion. Cardiac output data were made available to clinical
staff only on specific request. The reasons for this and
any subsequent changes in treatment were documented
by research staff. Dummy infusions were used in
patients not allocated to receive dopexamine. All other
management decisions were taken by clinical staff.
Sublingual microvascular flow
Sublingual microvascular flow was evaluated before sur-
gery and at 0, 2, 4, 6 and 8 hours immediately after sur-
gery using sidestream darkfield (SDF) imaging with a ×5
objective lens (Microscan, Microvision Medical, Amster-
dam, Netherlands) [32]. Image acquisition and subse-
quent analysis was performed according to published
consensus criteria [33]. SDF images were obtained from
at least three sublingual areas at each time point giving
a total of twelve quadrants for analysis. Vessel density
was calculated by inserting a grid of three equidistant
horizontal and three equidistant vertical lines over the
image. Vessel density is equal to the number of vessels
crossing these lines divided by their total length. Flow
was then categorised as present, intermittent or absent
to calculate the proportion of perfused vessels and thus
the perfused vessel density. Microvascular Flow Index
(MFI) was calculated after dividing each image into four
equal quadrants. Quantification of flow was determined
using an ordinal scale (0: no flow, 1: intermittent flow,
2: sluggish flow, 3: normal flow) for small (< 20 μm)
and large (> 20 μm) vessels. MFI is the average score of
all quadrants for a given category of vessel size at a
given time point. Analysis of the videos was performed
by two observers (AVS and SLA). The Kappa coefficient
() for inter-observer variability in SDF image analysis
was 0.74 (95% confidence interval 0.61 to 0.81). Baseline
sublingual large vessel MFI (> 20 μm) was 3.0 (3.0 to
3.0) in all groups suggesting good quality image capture
unaffected by pressure artefact.
Cutaneous microvascular flow and PtO2
Cutaneous red blood cell flux was measured before sur-
gery and at 0, 4 and 8 hours after surgery at two sites
on the forearm by laser Doppler flowmetry (Moorlab,
Moor Instruments, Axminster, UK). Baseline red cell
flux on the forearm was measured and following this,
the post-occlusive hyperaemic response was examined
by inflating a cuff around the upper arm to 20 mmHg
above systolic pressure for three minutes and measuring
the changes in red cell flux on releasing the pressure in
t h ec u f f .T h ed i f f e r e n c eb e t w e e nb a s e l i n ef l u xa n dp e a k
hyperaemia was then evaluated at each time point. Cuta-
neous tissue oxygen partial pressure (PtO2) was mea-
sured before surgery and at hour 0, 2, 4, 6 and 8 hours
after surgery at two sites on the abdominal wall using a
Clark electrode (TCM400, Radiometer, Copenhagen,
Denmark). PtO2 probes warm the skin to 44°C minimis-
ing artefact due to local vasoconstriction.
Arterial and venous blood gas analysis
Arterial and central venous blood samples were taken at
hour 0, 2, 4, 6 and 8 after surgery from indwelling
catheters for analysis of arterial haemoglobin saturation
with oxygen, ScvO2, base deficit and serum lactate
(ABL600, Radiometer, Copenhagen, Denmark).
Serum inflammatory markers
Serum samples were obtained from all patients following
induction of anaesthesia but prior to surgery. Further
serum samples were obtained immediately following
surgery, at the end of the intervention period and 24
hours after the end of surgery. These samples were cen-
trifuged at 3,000 g for 10 minutes and stored at -80°C.
Subsequent analysis of IL1 beta, IL6, IL8, and TNFa
was performed using a multi-array electro-chemilumi-
nescence technique (SECTOR Imager 2400, Mesoscale
Discovery, Gaithersburg, Maryland, USA). Levels of
soluble inter-cellular adhesion molecule 1 (ICAM-1)
were quantified using a similar technique.
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Clinical outcomes data for each patient were collected
by a member of the research team who was unaware of
study group allocation and then verified by the senior
investigator who was also unaware of the study group
allocation. Estimated glomerular filtration rate (eGFR)
was calculated preoperatively and on day seven after
surgery from serum creatinine, age, race and gender
using the Modification of Diet in Renal Disease equation
[34]. Patients were prospectively followed for 28 days for
pre-defined in-hospital complications, including acute
kidney injury within seven days [35], mortality and dura-
tion of hospital stay.
Statistical analysis
A s s u m i n ga5 %t y p eIe r r o r rate and an 80% type II
error rate, it was calculated that 45 patients would be
required in each group to detect a 10 mmHg difference
in PtO2 between each of the intervention groups and
the control group. Trends in physiological variables over
time within groups were tested using one-way repeated
measures analysis of variance (ANOVA) or Friedmann
test. Differences in physiological variables between
groups were tested using two-way repeated measures
ANOVA, the t test and one-way ANOVA with post hoc
t-test with Bonferroni correction. Categorical variables
were tested with the Chi squared or Fisher’s exact tests.
Statistical analysis was performed using GraphPad Prism
version 4.0 (GraphPad Software, San Diego, California
USA). Analysis was performed on an intention-to-treat
basis including all randomised patients. Significance was
set at P < 0.05. Data are presented as mean (standard
deviation) where normally distributed or median (inter-
quartile range) where not normally distributed.
Results
Between December 2007 and February 2009, 135
patients were recruited (Figure 1). Baseline patient char-
acteristics are presented in Table 1. Despite the different
haemodynamic treatment algorithms, patients in the
three groups received similar volumes of fluid during
and after surgery and there were no differences in
382 patients assessed for eligibility 
183 did not meet inclusion criteria 
26 refused or lacked capacity to consent 
26 did not undergo surgery as planned 
11 research staff unavailable 
1 already enrolled in interventional trial 
135 patients 
randomised 
45 patients 
assigned to  
CVP group 
All received 
intervention 
45 patients 
assigned to  
SV group 
All received 
intervention 
45 patients 
assigned to 
SV & DPX group 
All received 
intervention* 
45 patients 
included in 
analysis 
45 patients 
included in 
analysis 
45 patients 
included in 
analysis 
Figure 1 CONSORT diagram; flow of patients through trial.* O n ep a t i e n tr a n d o m i s e dt ot h eS V&D P Xg r o u pd e v e l o p e dm y o c a r d i a l
ischaemia during surgery (before the trial intervention commenced) and, in accordance with the protocol, did not receive dopexamine. CVP,
central venous pressure; DPX, dopexamine; SV, stroke volume.
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patients who received transfused blood during and after
surgery was similar between the groups as was the
volume of blood transfused (CVP group: 19 patients,
870 (580 to 1408) ml; SV group: 12 patients, 561 (398
t o5 8 0 )m l ;S V&D P Xg r o u p :1 5p a t i e n t s ,5 8 0( 3 0 0t o
877) ml; P = 0.11). One patient randomised to the SV &
DPX group developed myocardial ischaemia during sur-
gery and, in accordance with the study protocol, did not
receive dopexamine. In five patients the dose of dopexa-
mine was reduced because of an increase in heart rate
and in one patient, dopexamine was subsequently dis-
continued. On only one occasion, a clinician asked to
view a patient’s cardiac output data because of concern
that poor cardiac function might have been complicated
by pulmonary oedema. This information did not prompt
any changes in treatment. No patients received addi-
tional inotropic therapy during the intervention period.
Stroke volume-guided fluid therapy with dopexamine
infusion was associated with significant increases in
heart rate, cardiac index, DO2 and ScvO2.S t r o k e
volume-guided fluid therapy alone was associated with
much smaller increases in cardiac index and DO2 and
no change in heart rate or ScvO2 (Figure 2 and Table
3). In all three groups, microvascular flow was impaired
at baseline (Table 4). In the SV & DPX group, sublin-
gual microvascular flow significantly improved during
the eight-hour study period (Figure 3 and Table 4). Sub-
lingual microvascular flow remained constant in the SV
group but deteriorated in the control group (Figure 3).
Similarly, there was a significant improvement in the
cutaneous hyperaemic response in the SV & DPX
group, whereas this variable remained unchanged in the
SV group and deteriorated in the control group (Figure
3). In all three groups, cutaneous PtO2 initially increased
after surgery. This improvement was sustained in the SV
& DPX group but decreased towards baseline in the
CVP and SV groups (Figure 4).
There were no significant differences in overall compli-
cation rates, critical care free days or duration of hospital
stay, although the pattern of mortality was consistent
with a beneficial effect of stroke volume-guided haemo-
dynamic therapy (Table 5). During the first seven days
after surgery, eGFR increased significantly in the SV &
D P Xg r o u pb u tn o ti nt h eS Vo rt h eC V Pg r o u p( S V&
DPX group 21 [20] ml/min, P = 0.001; SV group 10 [33]
ml/min, P = 0.09; CVP group 2 [35] ml/min; P = 0.73).
Consequently, a post hoc analysis of the predefined renal
outcome was performed. Fewer patients developed acute
kidney injury in the pooled SV and SV & DPX groups
within seven days of surgery (P = 0.03; Table 5). Despite
improvements in tissue microvascular flow and oxygena-
tion in the SV and SV & DPX groups, there were no dif-
ferences between the groups in terms of the serum
inflammatory markers IL-1b,I L - 6 ,I L - 8 ,T N F a and
ICAM-1 within 24 hours of surgery (Figure 5).
Discussion
This is the first study to substantiate the theory that car-
diac output-guided haemodynamic therapy can improve
Table 1 Patient characteristics at baseline
CVP group
n =4 5
SV group
n =4 5
SV & DPX group
n =4 5
Age (years) 70 (64-78) 68 (59-77) 65 (59-74)
Male (%) 30 (67%) 31 (69%) 28 (62%)
ASA score 2 (2-3) 2 (2-3) 2 (2-3)
Upper gastrointestinal surgery (%) 18 (40%) 18 (40%) 18 (40%)
Pancreatic surgery involving gut (%) 18 (40%) 18 (40%) 18 (40%)
Lower gastrointestinal surgery (%) 9 (20%) 9 (20%) 9 (20%)
Data presented as median (IQR) or absolute values (%). ASA, American society of anesthesiologists; CVP, central venous pressure; DPX, dopexamine; SV, stroke
volume.
Table 2 Volume of intravenous fluid administered and use of vasopressor therapy in the three groups
CVP group
n =4 5
SV group
n =4 5
SV & DPX group
n =4 5
P
Intra-operative period
Intravenous crystalloid during surgery (ml) 3595 (1354) 4057 (1495) 4159 (1393) 0.15
Intravenous colloid during surgery (ml) 756 (815) 835 (688) 709 (559) 0.69
Intervention period
Intravenous crystalloid during study period (ml) 639 (281) 652 (237) 626 (250) 0.98
Intravenous colloid during study period (ml) 1104 (553) 1227 (555) 1307 (549) 0.22
Patients receiving vasopressor therapy (%) 7 (16%) 8 (18%) 5 (11%) 0.82
Data presented as mean (standard deviation) or absolute values (%). CVP, central venous pressure; DPX, dopexamine; SV, stroke volume.
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Page 5 of 12Figure 2 Changes in (a) oxygen delivery index and (b) central venous oxygen saturation following surgery in the three treatment
groups. *Significant difference between groups over time for oxygen delivery index (DO2I) and central venous oxygen saturation (ScvO2; P <
0.0001; two-way repeated measures analysis of variance). Significant increase in DO2I over time: SV group P = 0.003; SV & DPX group P < 0.0001.
Significant increase in ScvO2 over time: SV & DPX group P < 0.0001; no change in the SV group (P = 0.22) or CVP group (P = 0.98). †At hour
eight, there was a significant difference in DO2I between the CVP and SV & DPX groups (P < 0.001) but no difference between the SV and CVP
groups (P > 0.05). At hour eight, there was a significant difference in ScvO2 between the CVP and SV & DPX groups (P < 0.05) but no difference
between the SV and CVP groups (P > 0.05). CVP, central venous pressure; DPX, dopexamine; SV, stroke volume.
Table 3 Cardiovascular physiology for the three treatment groups during eight hour study period
Group Hour 0 Hour 2 Hour 4 Hour 6 Hour 8
Heart rate
(bpm)
CVP 74 (13) 76 (14) 76 (14) 76 (15) 76 (15)
SV 77 (19) 76 (17) 80 (19) 79 (17) 78 (17)
§ SV & DPX 77 (11) 86 (12) 91 (12) 93 (13) 92 (12)
Mean arterial pressure (mmHg) CVP 80 (22) 79 (20) 79 (15) 79 (15) 77 (14)
SV 76 (15) 81 (15) 83 (14) 79 (14) 77 (14)
† SV & DPX 80 (18) 83 (17) 84 (13) 77 (13) 74 (12)
Central venous pressure (mmHg) ‡ CVP 6 (5) 7 (5) 7 (5) 8 (5) 8 (5)
* SV 4 (5) 6(4) 6 (5) 7 (4) 7 (5)
† SV & DPX 5 (4) 7 (4) 7 (4) 8 (6) 8 (5)
Cardiac index
(l/min/m
2)
CVP 3.5 (1.1) 3.5 (0.9) 3.5 (0.9) 3.5 (0.9) 3.4 (0.9)
‡ SV 3.2 (0.9) 3.5 (0.9) 3.7 (1.0) 3.7 (1.0) 3.6 (1.0)
§ SV & DPX 3.3 (0.8) 4.0 (0.9) 4.3 (1.0) 4.3 (0.9) 4.4 (1.1)
Oxygen delivery index
(ml/min/m
2)
CVP 477 (146) 490 (144) 480 (152) 468 (168) 467 (159)
† SV 449 (145) 492 (160) 495 (147) 499 (165) 484 (150)
§ SV & DPX 498 (157) 594 (167) 635 (198) 631 (174) 614 (209)
Stroke volume
(ml)
CVP 80 (23) 86 (25) 84 (24) 82 (21) 81 (21)
‡ SV 78 (23) 85 (22) 84 (22) 85 (22) 83 (22)
‡ SV & DPX 80 (23) 88 (24) 90 (24) 89 (23) 88 (26)
Serum lactate
(mmol/l)
† CVP 1.4 (1.0-2.1) 1.1 (0.9-1.6) 1.1 (0.9-1.8) 1.2 (0.9-1.8) 1.2 (0.9-1.8)
* SV 1.4 (0.9-2.7) 1.3 (0.9-2.2) 1.3 (0.8-2.4) 1.2 (0.8-1.9) 1.2 (0.8-1.8)
SV & DPX 1.9 (1.3-2.8) 1.7 (1.0-2.4) 1.9 (1.0-2.9) 1.9 (1.0-3.1) 1.7 (1.1-2.4)
Base deficit
(mmol/l)
CVP -1.9 (2.6) -2.2 (2.7) -1.7 (2.8) -1.7 (2.9) -1.6 (2.6)
* SV -2.2 (2.4) -2.1 (2.8) -1.6 (3.1) -1.0 (2.2) -1.0 (2.3)
‡ SV & DPX -2.2 (2.1) -2.3 (2.4) -2.2 (2.4) -1.9 (2.3) -1.4 (2.4)
Data presented as mean (standard deviation) or median (interquartile range). Significant changes over time signified by † (P < 0.05), ‡ (P < 0.01), * (P < 0.001)
and § (P < 0.0001). CVP, central venous pressure; DPX, dopexamine; SV, stroke volume.
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that a treatment algorithm incorporating stroke volume-
guided fluid therapy and a low-dose dopexamine infusion
increased global DO2 and ScvO2 i na s s o c i a t i o nw i t hs i g n i f -
icant improvements in sublingual and cutaneous micro-
vascular flow and cutaneous tissue oxygenation. Stroke
volume-guided fluid therapy alone was associated with
more modest improvements in global haemodynamics and
microvascular flow. There were, however, no differences in
circulating markers of the inflammatory response to sur-
gery between treatment groups.
This randomised controlled trial used physiological
end-points and was not designed to identify differences
in clinical outcomes although a post hoc analysis did
identify a possible improvement in renal outcomes
(eGFR and incidence of acute kidney injury) associated
with stroke volume-guided therapy. This finding is con-
sistent with a recent meta-analysis suggesting that hae-
modynamic optimisation protects renal function in
surgical patients [31]. There was no reduction in overall
complication rates in the intervention groups and the
small difference in hospital mortality, although consis-
tent with improved outcome was not significant. To
achieve 80% power to detect a 25% reduction in the
relative risk of complications would require a minimum
of 150 patients in each of the three treatment groups.
Table 4 Sublingual microvascular flow for small vessels (< 20 μm) during eight hour study period
Hour 0 Hour 2 Hour 4 Hour 6 Hour 8
Microvascular Flow Index CVP 2.5 (0.3) 2.5 (0.7) 2.6 (0.4) 2.6 (0.4) 2.5 (0.5)
SV 2.5 (0.4) 2.5 (0.5) 2.6 (0.4) 2.7 (0.3) 2.6 (0.4)
† SV & DPX 2.5 (0.4) 2.4 (0.5) 2.5 (0.4) 2.7 (0.3) 2.5 (0.4)
Perfused vessel density
(mm
-1)
‡ CVP 6.1 (2.4) 6.1 (1.7) 5.8 (2.0) 5.8 (1.9) 5.3 (1.8)
SV 5.8 (2.5) 5.7 (2.6) 5.7 (1.9) 5.7 (1.9) 6.2 (3.0)
† SV & DPX 5.8 (2.4) 5.5 (2.4) 5.9 (2.8) 6.2 (1.8) 6.3 (3.0)
Proportion of perfused vessels CVP 0.83 (0.14) 0.83 (0.12) 0.81 (0.14) 0.82 (0.18) 0.81 (0.18)
SV 0.80 (0.15) 0.80 (0.21) 0.82 (0.17) 0.84 (0.13) 0.80 (0.19)
SV & DPX 0.81 (0.16) 0.77 (0.14) 0.81 (0.15) 0.85 (0.12) 0.87 (0.17)
Heterogeneity index CVP 0.39
(0.23-0.51)
0.23
(0.12-0.41)
0.25
(0.17-0.48)
0.28
(0.16-0.38)
0.25
(0.10-0.54)
SV 0.23
(0.10-0.43)
0.20
(0.07-0.31)
0.22
(0.04-0.41)
0.19
(0.06-0.31)
0.22
(0.08-0.46)
† SV & DPX 0.27
(0.18-0.40)
0.20
(0.14-0.44)
0.18
(0-0.27)
0.13
(0.08-0.27)
0.17
(0-0.38)
Data presented as mean (standard deviation) or median (interquartile range). Significant changes over time signified by † (P < 0.05), ‡ (P < 0.01). CVP, central
venous pressure; DPX, dopexamine; SV, stroke volume.
Figure 3 Changes in (a) sublingual perfused vessel density and (b) peak-baseline cutaneous red cell flux following three minutes of
vascular occlusion from hour 0 following surgery in the three treatment groups. *Significant difference between groups over time for
sublingual vessel density (P < 0.05) and cutaneous hyperaemic response (P < 0.01) (two-way repeated measures analysis of variance). Significant
increase in perfused sublingual vessel density over time in the SV & DPX group (P = 0.046), no change in the SV group (P = 0.58) and a decrease
in the CVP group (P = 0.005). Significant increase in cutaneous hyperaemic response over time in the SV & DPX group (P = 0.003), no change in
the SV group (P = 0.58) and a decrease in the CVP group (P = 0.03). †At hour eight, there was a significant difference in perfused sublingual
vessel density between the SV & DPX and CVP groups (P < 0.05) but not between the SV and CVP groups (P > 0.05). At hour eight, there was a
significant difference in cutaneous hyperaemic response between the SV & DPX and CVP groups (P < 0.001) but not between the SV and CVP
groups (P > 0.05). CVP, central venous pressure; DPX, dopexamine; SV, stroke volume.
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Page 7 of 12In common with all trials of complex interventions, it
was not possible to fully blind clinical staff to study
group allocation. We did, however, conceal study group
allocation from all investigators apart from the member
of the research team delivering the intervention. This
included concealment of cardiac output data and the
use of dummy infusions. All complications, including
acute kidney injury, were assessed according to prospec-
tively defined criteria and verified by the principal inves-
tigator who was unaware of study group allocation.
Lastly our stratified randomisation procedure ensured
that the three groups were comparable.
The importance of using cardiac output-derived data
to guide a carefully prescribed and consistently applied
clinical intervention is illustrated by the findings of a
previous multi-centre randomised trial in which per-
ioperative pulmonary artery catheterisation, in the
absence of improved haemodynamics, failed to influence
outcome [36]. In the study reported here, three clinically
relevant treatment algorithms were strictly implemented
by members of the research team throughout the eight-
hour intervention period. Perhaps as a consequence,
unlike most previous studies, the total volumes of intra-
venous fluid administered were similar between the
groups [12-18]. This suggests a high standard of care for
all patients that may have limited the apparent treat-
ment effect of stroke volume-guided fluid therapy. Inter-
estingly, the findings of one previous trial suggest that,
even where median fluid administration is similar
between groups, cardiac output-guided fluid therapy
may be associated with improved clinical outcomes [37].
The relation between derangements in cardiac output-
related variables and complications following major sur-
gery is well described [9-11]. The findings of some, but
not all clinical trials and a number of meta-analyses sug-
gest that cardiac output-guided haemodynamic therapy
can improve post-operative outcomes [12-18,30,31]. It
has long been assumed that the potential benefits of
‘flow guided’ peri-operative haemodynamic therapy
relate to improved tissue perfusion and oxygenation. A
number of studies have highlighted the significance of
impaired tissue microvascular flow in the pathogenesis
of post-operative complications [21-24]. In this context,
it is interesting to note that the use of high concentra-
t i o n so fi n s p i r e do x y g e nd i dn o ta f f e c tt h ei n c i d e n c eo f
post-operative wound infection or pneumonia in a
recent large clinical trial [38]. In the current study, the
u s eo faf i x e dl o w - d o s ei n o t r o p ei n f u s i o nc o u p l e dw i t h
stroke volume-guided fluid therapy resulted in increases
in heart rate and, to a lesser extent, stroke volume
which in turn increased DO2 and ScvO2 to values pre-
viously associated with improved clinical outcomes
Figure 4 Changes in tissue oxygenation following surgery in the
three treatment groups. *Significant difference between groups
over time (P = 0.0005; two-way repeated measures analysis of
variance). Significant increase in tissue oxygenation (PtO2) over time
in the SV & DPX group (P = 0.0003), no change in the SV (P = 0.14) or
CVP groups (P = 0.20). †At hour eight, there was a significant
difference in PtO2 between the SV & DPX and CVP groups (P < 0.005)
but not between the SV and CVP groups (P > 0.05). CVP, central
venous pressure; DPX, dopexamine; SV, stroke volume.
Table 5 Clinical outcomes in the three intervention groups
CVP group
n =4 5
SV group
n =4 5
SV & DPX group
n =4 5
P
Complications
(number of patients, %)
30 (67%) 26 (58%) 31 (69%) 0.51
Cardiac complications (number of patients, %) 4 (9%) 3 (7%) 3 (7%) 0.90
Infectious complications (number of patients, %) 29 (64%) 24 (53%) 28 (62%) 0.52
Other complications (number of patients, %) 10 (22%) 14 (31%) 12 (27%) 0.63
Acute kidney injury within 7 days of surgery 10 (22%) 3 (7%) 4 (9%) 0.055*
Critical care free days within 28 days of surgery 24 (21-26) 24 (21-26) 26 (21-27) 0.45
Duration of hospital stay (days) 15 (10-26) 14 (11-26) 16 (11-28) 0.73
Hospital mortality (%) 6 (13%) 5 (11%) 4 (9%) 0.45
Data presented as median (interquartile range) or absolute values (%). Note: A number of patients developed more than one complication. Acute kidney injury at
seven days not included in 28 day complication outcome.
*Significant difference in incidence of acute kidney injury between pooled SV and SV & DPX groups and the CVP group (P = 0.03, post hoc analysis). CVP, central
venous pressure; DPX, dopexamine; SV, stroke volume.
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Page 8 of 12[9-11]. We show for the first time that such increases in
global haemodynamics are associated with improve-
ments in tissue microvascular flow and oxygenation,
thus validating the study’s hypothesis. Although stroke
volume-guided intravenous colloid therapy led to much
smaller increases in cardiac index and DO2,w i t hn o
change in heart rate or ScvO2,m i c r o v a s c u l a rf l o ww a s
better maintained than in the CVP-guided therapy
group. The incremental effects of low dose dopexamine
on both microvascular flow and tissue oxygenation are
Figure 5 Changes in (a) serum IL-1b, (b) IL-6, (c) IL-8, (d) TNFa and (e) soluble inter-cellular adhesion molecule 1 between the three
treatment groups. Data presented as mean (standard error). There were no significant differences between the groups. CVP, central venous
pressure; DPX, dopexamine; ICAM-1, inter-cellular adhesion molecule 1; SV, stroke volume.
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Page 9 of 12likely to relate to the b2-adrenoceptor-mediated inotro-
pic and vasodilator actions of this agent. It is therefore
possible that changes in microvascular flow relate to
direct effects on the microcirculation as well as global
cardiac output.
Interestingly, in a recent randomised trial, low-dose
nitroglycerin had no effect on sublingual microvascular
flow in resuscitated patients with severe sepsis [39].
These contrasting findings may reflect differences in the
nature and timing of the intervention as well as the
patient population and smaller sample size. In contrast,
the use of vasopressor and inotropic agents has been
shown to improve both tissue microvascular flow and
oxygenation in patients with severe sepsis [28,29],
although these effects were not demonstrated in all such
investigations [40,41]. While, these studies do suggest
potential effects of vasoactive drugs on microvascular
flow, the current study is the first to investigate the
effects of the use of cardiac output-based end-points on
tissue microvascular flow and oxygenation.
The simultaneous use of three different modalities to
assess different aspects of tissue microvascular function
was an important strength of this investigation. SDF ima-
ging is a non-invasive technique that provides a real-time
video image of the intact microcirculation. However, this
technique is limited by semi-quantitative analysis and the
fact that it can only be used to image the microcircula-
tion under mucosal surfaces. Laser Doppler flowmetry is
a technique based on the Doppler shift of reflected laser
light from moving red blood cells. This method cannot
distinguish the size or type of microvessel, direction of
flow or heterogeneity of flow, all of which may be impor-
tant in critically ill or high-risk surgical patients. These
limitations can be addressed through the measurement
of post-occlusion reactive hyperaemia, which provides a
reproducible assessment of endothelium-dependant
microvascular response [42]. The cutaneous Clarke elec-
trode measures the local partial pressure of oxygen by a
polarographic method. If tissue perfusion decreases while
partial pressure of oxygen (PaO2) remains constant, cuta-
neous PtO2 will decrease thus linking peripheral perfu-
sion and tissue oxygenation [43]. The consistent patterns
of change identified with each of the three modalities is
therefore of particular importance. However, these meth-
ods have been used to assess quite different aspects of
microvascular function and cannot be directly compared.
We have presented the changes in microvascular flow in
terms of change from the baseline values. While differ-
ences are less apparent on analysis of absolute values, the
consistency of the changes we observed between three
distinct measures of tissue perfusion strongly suggests
that these findings are robust.
Conclusions
A treatment algorithm incorporating stroke volume-
guided fluid therapy plus low-dose dopexamine infusion
was associated with significant improvements in micro-
vascular flow and tissue oxygenation but no change in
the inflammatory response to surgery. These physiologi-
cal changes may explain the beneficial effects of cardiac
output-guided haemodynamic therapy demonstrated in
previous clinical trials. Our findings strongly support the
need for large multi-centre trials to evaluate the clinical
effectiveness of cardiac output-guided haemodynamic
therapy. Several such trials are now under way in
patients with severe sepsis, those undergoing major
surgery and in potential organ donors.
Key messages
￿ Peri-operative haemodynamic therapies guided by
cardiac output monitoring have been associated with
improved clinical outcomes in small clinical trials.
￿ The mechanism of therapeutic benefit is believed
to relate to improved tissue perfusion and oxygen
delivery but this theory has not previously been
tested.
￿ In this study, stroke volume-guided fluid therapy
and low-dose dopexamine infusion was associated
with improvements in tissue microvascular flow and
oxygenation but clinical outcomes were similar
between groups.
￿ These findings may explain the improved clinical
outcomes reported in previous studies. Large rando-
mised trials are now required to confirm the clinical
benefits of this treatment approach.
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